Drug Trial Radar · NCT05531097
Ascending Single-Dose and Multiple-Dose Study to Evaluate HSK31679 in Healthy Subjects and Subjects With Elevated LDL-C
Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Feb 22, 2022
Primary completion
Sep 21, 2022
Study completion Dec 8, 2022
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, single-dose and multiple dose escalation clinical trial for HSK31679 conducted in chinese healthy volunteers and LDL-C elevated subjects. The safety, tolerability, food-impact,pharmacokinetics and pharmacodynamics of HSK31679 tablet in healthy volunteers and LDL-C elevated volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design
Conditions
- Healthy
- Elevated LDL-C
Interventions
HSK31679Drug
Single or multiple oral doses of HSK31679
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number and severity of treatment emergent adverse events (TEAEs) .Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
- Changes from baseline in clinical laboratory parameters(Blood routine, blood biochemistry, Urine routine, Coagulation function, thyroid function and antibodies).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
- Changes from baseline in physical examination results(General condition skin mucous membrane superficial lymph nodes head neck chest abdomen spine limbs and others).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
- Changes from baseline in vital signs(Systolic and diastolic blood pressure, pulse, respiratory rate, body temperature).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
- Changes from baseline in 12-ECG(QT interval, QTcF interval, PR interval, QRS interval and RR interval).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital of Central South University
Changsha, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.